1,274 results on '"Yoon, Dok-Hyun"'
Search Results
52. The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma
53. P-135 Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: a nationwide cohort study by the Korean multiple myeloma working party (KMM 2202)
54. Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation
55. Prognostic significance of 25-hydroxyvitamin D levels in patients with peripheral T-cell lymphoma
56. S224: HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY
57. PB2338: BONE MARROW INVOLVEMENT IN KOREAN PATIENTS WITH LYMPHOMAS: A 21-YEAR LARGE SINGLE-CENTER STUDY
58. Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
59. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group
60. The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms
61. Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy
62. Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study
63. The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma]{The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma
64. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
65. Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients
66. Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response
67. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
68. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
69. Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
70. Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma
71. Radioimmunotherapy with 131I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma.
72. Abstract CT130: An open label, dose escalation, phase 1 study of AT101, a novel CD19-directed CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma
73. Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
74. Evaluation of laboratory diagnostic tests for light-chain clonality and bone marrow findings in AL amyloidosis
75. Supplementary Methods and Materials, Figures S1-S3, Tables S1-S5 from Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
76. Supplementary Appendix, Tables 1-5, Figures 1-3 from FDG-PET as a Potential Tool for Selecting Patients with Advanced Non–Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy
77. Radioimmunotherapy with 131I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma
78. A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea
79. Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma
80. Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine
81. PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma
82. Sexual problems in male vs. female non-Hodgkin lymphoma survivors: prevalence, correlates, and associations with health-related quality of life
83. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
84. A prospective study of preemptive tenofovir disoproxil fumarate therapy in HBsAg-positive diffuse large B cell lymphoma patients receiving R-CHOP
85. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
86. Prognostic Significance of Vitamin D Level in Patients with Multiple Myeloma
87. Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)
88. Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma
89. Prognostic Significance of Vitamin D Level at Diagnosis in Patients with Peripheral T-Cell Lymphoma
90. Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
91. ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas
92. Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma
93. Safety and Effectiveness of Rituximab Biosimilar CT-P10 during Routine Clinical Practice: Final Analysis of a Post-Marketing Surveillance Study in the Republic of Korea
94. Clinical Significance of Epstein-Barr Virus in Peripheral T-Cell Lymphoma, Not Otherwise Specified
95. Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation
96. Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL
97. LGALS3 as a prognostic factor for classical Hodgkin's lymphoma
98. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy
99. The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea
100. Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.